| we demonstrate that oncogenic p110alphaH1047R, K-RasG12V, H-RasG12V, and Her2 use a common Akt1-FOXO3a pathway in suppression of DeltaNp63alpha expression and, consequently, promote cell migration/invasion and tumor metastasis. Thus, DeltaNp63alpha may function as a critical integrator of oncogenic signals in cell motility and cancer metastasis. | None |
| Localization of Evi-2 to chromosome 11: linkage to other proto-oncogene and growth factor loci using interspecific backcross mice. | None |
| Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. | None |
| Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. | None |
| p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. | None |
| erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. | None |
| Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. | None |
| Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. | None |
| Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. | None |
| Production and characterization of monoclonal antibodies to the c-erbB-2 proto-oncogene protein using a synthetic peptide immunogen. | None |
| The role of the neu oncogene product in cell transformation and normal development. | None |
| Data indicate that the changes of proto-oncogene protein HER-2 (HER2) copy number in ctDNA could efficiently monitor trastuzumab efficacy. | None |
| The objective of this study was to determine if loss of Stard13 plays a role in mammary tumor progression using transgenic mice expressing the activated ErbB-2 (Neu) oncogene and Cre recombinase (NIC) in mammary epithelium under transcriptional control of the murine mammary tumor virus (MMTV) promoter (MMTV-NIC). | None |
| Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. | None |
| Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. | None |
| Data showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of proto-oncogene protein HER-2 (HER2) status is essential before any therapeutic decision. | None |
| Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. | None |
| Exploration of the Structure and Recognition of a G-quadruplex in the her2 Proto-oncogene Promoter and Its Transcriptional Regulation. | None |
| The potential roles of several oncogenic pathways (phosphatase and tensin homolog (PTEN) and phosphatidylinositol 3-kinase (PI3K)) in relation to HER2 status. | None |
| Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. | None |